Recombinant HIV-1 virus with the indicated mutations in the protease gene. Mutations have been reported from drug resistant viral variants emerging in vivo, e.g. after treatment with the HIV protease inhibitor saquinavir
Recombinant HIV-1 plasmid (derived from pNL4-3) with the indicated mutations in the protease gene, which have been reported in the context of clinical drug resistance to HIV protease inhibitors.
Plasmid containing entire HIV-1 (NL4-3) with the indicated mutations in the HIV-1 protease gene. The respective mutations have been identified in vivo in specimens from individuals failing antiretroviral therapy with protease inhibitors.
Plasmid contains the entire genome of HIV-1 (NL4-3) with the respective specific mutations in the protease gene. These may confer drug resistance to specific HIV protease inhibitors and have been identified in clinical specimens from individuals with therapeutic failure.
